A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
P274 Comparison of the initiation of copd treatment with licensed fdc ics/laba treatments in terms of disease control and cost effectiveness
Pharmacotherapies for COPD
per year) versus 25 pneumonias (rate: 0.039 events per patient per year) with fixed triple and 353 exacerbations (0.565) versus 18 pneumonias (0.029) with Fostair ( figure 1A ). In TRINITY study, the number of events was 485 exacerbations (0.472) versus 30 pneumonias (0.029) with fixed triple and 569 exacerbations (0.583) versus 20 pneumonias (0.020) with tiotropium ( figure 1B) . Overall, treatment with fixed triple therapy reduced exacerbations by 65 events compared to Fostair (adjusted ratedoi:10.1136/thoraxjnl-2017-210983.416 fatcat:mauejwzievgcvcrzrmjf7zv5qy